KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema.
Am J Ophthalmol. 2022 Jun;238:157-172. doi: 10.1016/j.ajo.2022.01.004. Epub 2022 Jan 14.
Am J Ophthalmol. 2022.
PMID: 35038415
Free article.
Clinical Trial.